Literature DB >> 24498993

HLA alleles and HLA-B27 haplotypes associated with susceptibility and severity of ankylosing spondylitis in a Portuguese population.

F M Pimentel-Santos1, M Matos, D Ligeiro, A F Mourão, C Ribeiro, J Costa, H Santos, A Barcelos, P Pinto, M Cruz, E Sousa, R A Santos, J E Fonseca, H Trindade, H Guedes-Pinto, J C Branco.   

Abstract

Human leukocyte antigen (HLA)-B27 is the mostly known major histocompatibility complex (MHC) gene associated with ankylosing spondylitis (AS). Nonetheless, there is substantial evidence that other MHC genes appear to be associated with the disease, although it has not yet been established whether these associations are driven by direct associations or by linkage disequilibrium (LD) mechanisms. We aimed to investigate the contributions of HLA class I and II alleles and B27-haplotypes for AS in a case-control study. A total of 188 HLA-B27 AS cases and 189 HLA-B27 healthy controls were selected and typed for HLA class I and II by the Luminex polymerase chain reaction-sequence specific oligonucleotide probe (PCR-SSOP) method. Allelic and haplotypic distributions were estimated by maximum likelihood method using Arlequin v3.11 and statistical analysis were performed by Stata10.1. No associations were found between non-HLA-B27 loci and AS susceptibility, but several associations were observed for phenotypic features of the disease. DRB1*08 was identified as a risk factor for uveitis and DQB1*04 seems to provide protection for AS severity (functional, metrological and radiological indexes). A*02/B27/C*02/DRB1*01/DQB1*05 [P<0.0001; odds ratio (OR) = 39.06; 95% confidence interval (CI) (2.34-651)] is the only haplotype that seems to confer susceptibility to AS. Moreover, the haplotype A*02/B27/C*01/DRB1*08/DQB1*04 seems to provide protection for disease functional and radiological repercussions. Our findings are compatible with the hypothesis that other genes within the HLA region besides HLA-B27 might play some role in AS susceptibility and severity.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  B27‐haplotypes; HLA alleles; HLA class I and II; ankylosing spondylitis; phenotypic features

Mesh:

Substances:

Year:  2013        PMID: 24498993     DOI: 10.1111/tan.12238

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  6 in total

1.  The Effect of ACTN3 and VDR Polymorphisms on Skeletal Muscle Performance in Axial Spondyloarthropathies.

Authors:  Isabel Pimenta; Hugo Mateus; Santiago Rodrigues-Manica; Rita Pinheiro-Torres; Agna Neto; Lúcia Domingues; Carolina Lage Crespo; Atlas Sardoo; Pedro Machado; Jaime C Branco; Susana N Silva; Fernando M Pimentel-Santos
Journal:  Front Genet       Date:  2021-08-11       Impact factor: 4.599

2.  Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2.

Authors:  Marharyta Petukh; Bohua Wu; Shannon Stefl; Nick Smith; David Hyde-Volpe; Li Wang; Emil Alexov
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

Review 3.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

4.  Genome-wide DNA methylation profile analysis identifies differentially methylated loci associated with ankylosis spondylitis.

Authors:  Jiangcan Hao; Yang Liu; Jiawen Xu; Wenyu Wang; Yan Wen; Awen He; Qianrui Fan; Xiong Guo; Feng Zhang
Journal:  Arthritis Res Ther       Date:  2017-07-25       Impact factor: 5.606

Review 5.  Best practices in DNA methylation: lessons from inflammatory bowel disease, psoriasis and ankylosing spondylitis.

Authors:  Jessica M Whyte; Jonathan J Ellis; Matthew A Brown; Tony J Kenna
Journal:  Arthritis Res Ther       Date:  2019-06-03       Impact factor: 5.156

6.  Risk factors of uveitis in ankylosing spondylitis: An observational study.

Authors:  Li Sun; Rui Wu; Qin Xue; Feng Wang; Peirong Lu
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.